ASTRO 2022 | Impact of HSD3B1 gene alterations on treatment response in patients with prostate cancer

Omar Mian, MD, PhD, Cleveland Clinic, Cleveland, OH, presents a trial that investigated whether HSD3B1 gene alteration modulates response to therapy in patients with prostate cancer. HSD3B1 encodes an enzyme involved in androgen production, which drives prostate cancer. The study found that variations in HSD3B1 genotype impacts the response to combination therapies in prostate cancer patients, suggesting that there is potential to use HSD3B1 as a predictive biomarker of response. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.